Drug Type Antibody drug conjugate (ADC) |
Synonyms CBT 005, CBT005 |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Cloudbreak Therapeutics LLCStartup |
Active Organization Cloudbreak Therapeutics LLCStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic macular oedema | Preclinical | US | Cloudbreak Therapeutics LLCStartup | 30 Jan 2022 |
Wet age-related macular degeneration | Preclinical | US | Cloudbreak Therapeutics LLCStartup | 30 Jan 2022 |